Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Mar 3;49(1):17–25. doi: 10.2478/raon-2014-0030

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © by Association of Radiology & Oncology

This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).

PMC Copyright notice

FIGURE 4. — A patient with squamous cell carcinoma of the head and neck. Before cetuximab treatment: (A) PET/CT fusion imaging showing the anatomical location of FDG uptake. (B) CT imaging with the regions of interest used for kinetic analysis. (C) ADC mapping derived from DW-MRI with a measured ADC^lesion = 1009 mm².s⁻¹ ± 123 mm².s⁻¹. (D) Spin Echo T1-weighted MR imaging with fast suppression technique (SPIR) after gadolinium injection (lesion long axis: 2.88 cm, lesion short axis: 1.52 cm). MRI examination was performed 6 days after PET/CT. During treatment with cetuximab: (E) PET/CT fusion showing imaging of the decrease of FDG uptake. (F) CT imaging with the regions of interest used for kinetic analysis. (G) ADC mapping derived from DW-MRI with an increased ADC^lesion = 1325 mm².s⁻¹ ± 192 mm².s⁻¹. (H) Spin Echo T1-weighted MR imaging with fast suppression technique (SPIR) after gadolinium injection (lesion long axis: 2.72 cm, lesion short axis: 1.12 cm). MRI and CT examinations were performed the same day.